Rezolute reports first use of RZ358 for insulinoma; patient achieved substantial hypoglycemia benefit

Rezolute, Inc.

Patient with metastatic insulinoma and intractable hypoglycemia received RZ358 under compassionate use IND.
Treatment began Q4 2022; patient continues therapy with substantial benefit and improved quality of life per Dr. Patti.
Case presented as late-breaking abstract at ENDO 2023 on June 16, 2023; abstract published in Journal of Endocrine Society.
This marks the first time Rezolute's RZ358 has been used for insulinoma indication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.